Lyra Therapeutics (LYRA) Cash from Investing Activities (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Cash from Investing Activities for 7 consecutive years, with -$96000.0 the latest figure, recorded in Q4 2025.

• Cash from Investing Activities for Q4 2025 came in at -$96000.0, down 100.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $36.2 million (down 54.95% YoY), and the FY2025 annual result was -$98000.0, down 100.12% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at -$96000.0, down from $28.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $36.2 million in Q2 2024, with the low at -$64.9 million in Q4 2022.
• A 5-year average of -$45058.8 and a median of -$96000.0 in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities tumbled 51551.72% in 2023 and surged 6548.48% in 2024, its largest moves.
• Lyra Therapeutics' Cash from Investing Activities stood at -$1.1 million in 2021, then sank by 5889.84% to -$64.9 million in 2022, then surged by 96.36% to -$2.4 million in 2023, then jumped by 1292.5% to $28.1 million in 2024, then tumbled by 100.34% to -$96000.0 in 2025.
• The last three Cash from Investing Activities figures came in at -$96000.0 (Q4 2025), $28.1 million (Q4 2024), and $8.1 million (Q3 2024), per Business Quant data.